EKR Therapeutics Acquires Exclusive License for Gelclair(R) from Helsinn Healthcare SA.EKR eKr Ennen Kristusta (Finnish: Before Christ) EKR Eigenkapitalrendite (German: Return on Equity) Launches Initial Product in Portfolio Focused on Oncology Supportive Care supportive care, n medical and other interventions that attempt to support and make comfortable rather than to cure. CEDAR KNOLLS, N.J. -- EKR Therapeutics, Inc. has signed an agreement to acquire exclusive North American North American named after North America. North American blastomycosis see North American blastomycosis. North American cattle tick see boophilusannulatus. license and distribution rights for Gelclair([R]) from Helsinn Healthcare SA, a privately owned pharmaceutical company headquartered in Switzerland. Gelclair([R]) is the product specifically designed and approved by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. for the management of pain associated with oral mucositis / stomatitis Stomatitis Definition Inflammation of the mucous lining of any of the structures in the mouth, which may involve the cheeks, gums, tongue, lips, and roof or floor of the mouth. . "This is a significant milestone for EKR," commented Howard Weisman, Chairman & CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. . "Gelclair([R]) is the first of several planned product acquisitions in the area of oncology supportive care. These types of products are becoming an increasingly essential part of the total care of cancer patients as they help to improve the quality of life while undergoing aggressive treatments in a variety of tumor tumor: see neoplasm. types." "We are excited about our partnership with Helsinn, which markets Gelclair([R]) successfully through top tier companies around the world," says Cathy Kerzner, President & COO. "The acquisition of Gelclair([R]) coincides with the launch of our US sales force, which will be working with key institutions and private practice physicians to incorporate Gelclair([R]) into their treatment plans for patients suffering from oral mucositis." "Helsinn is delighted to enter this new agreement with EKR Therapeutics," said Dr. Riccardo Braglia, Managing Director of Helsinn Healthcare, and is confident that EKR Therapeutics will successfully secure Gelclair([R]) a first ranking position in the North American market and thereby allow patients in this territory suffering from oral mucositis/stomatitis to benefit from this drug and improve their quality of life. Gelclair is a bio-adherent oral gel with a mechanical action indicated for the management of pain and relief of pain by adhering to the mucosal surface of the mouth, soothing oral lesions of various etiologies, including oral mucostis/stomatitis which may be caused by chemotherapy or radiation therapy. Oral mucositis has been reported in 15-40% of patients receiving stomatoxic chemotherapy or radiotherapy, 70-90% of stem cell stem cell In living organisms, an undifferentiated cell that can produce other cells that eventually make up specialized tissues and organs. There are two major types of stem cells, embryonic and adult. transplant recipients, and 100% of patients receiving head and neck radiotherapy (doses >5000 cGy). Severe oral mucositis may result in a reduction in the dose of chemotherapy or a delay in treatment. About EKR Therapeutics, Inc. EKR Therapeutics (www.ekrtx.com) was founded to provide prescription products and therapeutic solutions that support and improve the quality of life of cancer patients. As new and increasingly effective therapies emerge, more patients survive cancer. Oncology supportive care is becoming an increasingly critical component in support of patients as they progress through the complex arena of oncology treatment. The management team of EKR believes that cancer survival is largely impacted by the appropriate management of side effects Side effects Effects of a proposed project on other parts of the firm. encountered by patients undergoing therapy. EKR Therapeutics is committed to collaborating with the full scope of healthcare practitioners in helping patients adhere to adhere to verb 1. follow, keep, maintain, respect, observe, be true, fulfil, obey, heed, keep to, abide by, be loyal, mind, be constant, be faithful 2. primary treatment through the use of supportive care products. About Helsinn Healthcare SA Helsinn Healthcare is a privately owned pharmaceutical group with headquarters in Switzerland and is worldwide licensor of Gelclair([R]). Helsinn's core business is the licensing of pharmaceuticals in niche therapeutic areas. The company's business strategy is to in-license early stage new chemical entities and complete their development by performing pre-clinical and clinical studies and CMC (Common Messaging Calls) A programming interface specified by the XAPIA as the standard messaging API for X.400 and other messaging systems. CMC is intended to provide a common API for applications that want to become mail enabled. 1. development through the attainment of market approval in strategic markets (US and Europe). Helsinn's products are subsequently out-licensed to its marketing partners for distribution. The active pharmaceutical ingredients and the finished dosage forms are manufactured at Helsinn's cGMP facilities and supplied worldwide to its customers. For more information about Helsinn please visit www.helsinn.com |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion